Partial
Partial Aligned
Patient Risk:
Medium
Summary
The response contains some label-consistent foundational statements (indication nuance for BH4-responsive PKU, synthetic BH4 description, and mechanism to decrease blood phenylalanine). However, many claims about disease cause, symptom/cognitive/behavioral/seizure outcomes, and specific adverse effects are not supported by the provided label sections, and the label excerpt set lacks key safety sections, limiting full on-label alignment.
Category Scores
Accurate Statements
Sapropterin is a synthetic form of tetrahydrobiopterin (BH4).
11 DESCRIPTION: described as a synthetic preparation of the dihydrochloride salt of naturally occurring BH4.
BH4 is a co-factor for the enzyme phenylalanine hydroxylase (PAH) and is involved in conversion of phenylalanine to tyrosine.
12.1 Mechanism of Action: PAH hydroxylates Phe through oxidative reaction to form tyrosine; BH4 is the cofactor for PAH.
Sapropterin treatment can reduce blood levels of phenylalanine.
1 INDICATIONS AND USAGE: indicated to reduce blood phenylalanine (Phe) levels; 12.1 and 14 describe decreased Phe levels in some patients and clinical study reductions.
Some patients may not respond to sapropterin treatment.
14 CLINICAL STUDIES: response defined (e.g., ≥30% decrease); only a subset are identified as responders (e.g., 20% responders in Study 1).
Unsupported Statements
In patients with PKU, the body is unable to produce enough BH4, leading to accumulation of toxic levels of phenylalanine.
Not supported by the provided label excerpts; the provided mechanism discusses absent/deficient PAH activity in PKU and activation of residual PAH, but does not state BH4 production deficiency or 'toxic levels' from BH4 deficiency.
Sapropterin works by increasing the production of BH4.
12.1 describes sapropterin as exogenous synthetic BH4 that activates residual PAH; it does not state that sapropterin increases endogenous BH4 production.
Sapropterin improves the body's ability to use phenylalanine for protein synthesis.
No such claim is present in the provided label excerpts.
Sapropterin has been shown to improve symptoms in patients with PKU.
Not supported by the provided label excerpts (clinical study descriptions provided focus on blood Phe response and do not mention symptom improvement).
Sapropterin treatment can improve cognitive function.
Not supported by the provided label excerpts.
Sapropterin treatment can reduce the severity of seizures.
Not supported by the provided label excerpts.
Sapropterin treatment can improve behavior and mood.
Not supported by the provided label excerpts.
Some patients may experience side effects such as headaches and nausea.
6 ADVERSE REACTIONS is empty in the provided label sections; no adverse reactions details are available to support this.
Sapropterin is not a cure for PKU.
No 'cure' statement is present in the provided label excerpts.
Sapropterin treatment is an important tool in the management of PKU.
The provided label sections do not include this management framing.
Sapropterin treatment resulted in significant improvements in cognitive function and behavior in patients with PKU in a 12-month study.
Not supported by the provided label excerpts; provided study descriptions (Studies 1-5) do not mention 12-month cognitive/behavior outcomes.
In the 12-month study, sapropterin treatment improved patients' ability to learn and remember new information.
Not supported by the provided label excerpts.
In the 12-month study, sapropterin treatment improved patients' behavior and mood.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Sapropterin is a medication used to treat phenylketonuria (PKU).
Label Reference
1 INDICATIONS AND USAGE: indicated to reduce blood Phe levels in adult and pediatric patients with hyperphenylalaninemia due to BH4-responsive PKU, used with a Phe-restricted diet.
Important Omissions
Use with a Phe-restricted diet (dietary use is stated in the indication but not reflected in the provided claims).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported symptom/cognitive/seizure/behavior claims and specific adverse effects (headaches/nausea) are not supported by the provided label sections. Additionally, the provided label excerpts omit major safety sections (contraindications/warnings/adverse reactions/dosing), so safety alignment cannot be fully verified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partial Aligned
Primary Issue
Multiple high-level efficacy/safety claims (cognitive/behavior/seizure outcomes and specific side effects) are unsupported by the provided prescribing information sections.
Suggested Improvement
Constrain claims to what is supported: (1) indication to reduce blood Phe in adult/pediatric patients with hyperphenylalaninemia due to BH4-responsive PKU and use in conjunction with a Phe-restricted diet; (2) mechanism that BH4 activates residual PAH to decrease Phe levels in some patients; (3) response defined subset (some non-responders). Avoid unlabelled symptom, cognitive/behavior, seizure, and specific adverse reaction examples unless supported by the full adverse reactions and clinical study sections.